CurveBeam Al Limited (ASX: $CVB) Quarterly 4C Conference Call Presentation

CurveBeam Al Limited (ASX: $CVB) presented its Quarterly 4C Conference Call, reporting that it received purchase orders for 10 devices in Q4, up from 6 in Q3, representing A$4.9m of revenue carried into FY25. The Company also submitted its 510(k) application for the enhanced HiRiseTM in Q4 FY24, with FDA clearance expected in Q1 FY25. Additionally, it maintains a target of mid-CY25 for FDA clearance of the BMD (bone mineral density) software module.

Executive Commentary on Progress and Outlook

The progress made in the development of the Enhanced HiRiseTM platform and the anticipated FDA clearance for the BMD module by mid CY25 are significant milestones for CurveBeam Al. The Company's focus on enhancing its offerings and targeting key anatomical landmarks for processing robotic surgical system guides demonstrates its commitment to innovation and addressing the needs of the medical community. We remain confident in the progress and outlook for the Company's products and are committed to a prudent approach to capital management.

Summary of Quarterly 4C Conference Call Presentation

CurveBeam Al Limited (ASX: $CVB) reported a significant increase in purchase orders for its devices, with a focus on the enhanced HiRiseTM platform and the development of the BMD module. The Company targets FDA clearance for the BMD module by mid CY25, aiming to offer a Software-as-a-Service (SaaS) annuity stream for sales and profit growth. Despite a decrease in full year revenue for FY24, the Company remains optimistic about the progress and outlook for its products, maintaining a prudent approach to capital management and considering further programs to reduce the cost base. With the anticipated milestones in FDA clearance and product development, CurveBeam Al is poised for continued growth and innovation in the medical imaging industry.